Press Releases InDex Pharmaceuticals Holding AB

Equities

INDEX

SE0008966295

Market Closed - Nasdaq Stockholm Other stock markets 08:59:53 03/05/2024 pm IST			5-day change	1st Jan Change
0.387 ^SEK	+1.31%		+5.16%	+51.17%

26/04	InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05/04	Index Pharmaceuticals Holding AB Announces Board Resignations	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InDex Pharmaceuticals Holding AB (publ) interim report January - March 2024	26/04	AQ
InDex Pharmaceuticals brings forward the publication of the interim report for Q1 2024	22/04	AQ
InDex Pharmaceuticals provides a company update	08/04	AQ
InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2023	08/04	AQ
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)	05/04	AQ
CEO and CFO both to leave InDex Pharmaceuticals	26/03	AQ
InDex Pharmaceuticals provides an update on company's future	26/02	AQ
InDex Pharmaceuticals discontinues the development of cobitolimod	26/02	AQ
InDex Pharmaceuticals Holding AB (publ) year-end report 2023	21/02	AQ
InDex Pharmaceuticals announces expected cash balance per March 31, 2024	19/01	AQ
InDex Pharmaceuticals Holding AB interim report January-September 2023	29/11	AQ
InDex Pharmaceuticals Q3 2023 - Uncertain future post discontinuation of CONCLUDE	29/11	AQ
InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023	28/11	AQ
InDex Pharmaceuticals discontinues cobitolimod phase III program	22/11	AQ
InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2024 Annual General Meeting	30/23/30	AQ
InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea	23/23/23	AQ
InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea	20/23/20	AQ
InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE	11/23/11	AQ
InDex Pharmaceuticals is attending the UEGW 2023 congress	05/23/05	AQ
InDex Pharmaceuticals Holding AB - Positive results from PK study with cobitolimod selected as one of the best abstracts for poster presentation at UEGW	23/23/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases InDex Pharmaceuticals Holding AB

Equities

INDEX

SE0008966295

Press Releases

Filters